China Health Group Bilan de santé

Santé financière contrôle des critères 5/6

China Health Group possède un total de capitaux propres de HK$59.8M et une dette totale de HK$5.5M, ce qui porte son ratio d'endettement à 9.2%. Son actif total et son passif total sont HK$192.3M et de HK$132.6M.

Informations clés

9.2%

Ratio d'endettement

HK$5.51m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	HK$8.98m
Fonds propres	HK$59.75m
Total du passif	HK$132.56m
Total des actifs	HK$192.32m

Mises à jour récentes de la santé financière

We Think China Health Group (HKG:673) Has A Fair Chunk Of Debt

Dec 01

Recent updates

Here's Why China Health Group Limited's (HKG:673) CEO Compensation Is The Least Of Shareholders' Concerns

Sep 05

Shareholders Will Probably Not Have Any Issues With China Health Group Limited's (HKG:673) CEO Compensation

Sep 11

We Think China Health Group (HKG:673) Has A Fair Chunk Of Debt

Dec 01

We Discuss Why China Health Group Limited's (HKG:673) CEO May Deserve A Higher Pay Packet

Sep 23

We Think Some Shareholders May Hesitate To Increase China Health Group Limited's (HKG:673) CEO Compensation

Sep 02

Did China Health Group Limited (HKG:673) Insiders Sell Shares?

Feb 16

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 673 ( HK$129.0M ) dépassent ses passifs à court terme ( HK$112.1M ).

Passif à long terme: Les actifs à court terme de 673 ( HK$129.0M ) dépassent ses passifs à long terme ( HK$20.5M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 673 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 673 est passé de 0% à 9.2% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: 673 dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: 673 devrait disposer d'une marge de trésorerie suffisante pour 9 mois sur la base des estimations de flux de trésorerie disponible, mais a depuis levé des capitaux supplémentaires.

China Health Group Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

We Think China Health Group (HKG:673) Has A Fair Chunk Of Debt

Recent updates

China Health Group Limited to Report First Half, 2025 Results on Nov 29, 2024

New minor risk - Share price stability

New minor risk - Share price stability

Here's Why China Health Group Limited's (HKG:673) CEO Compensation Is The Least Of Shareholders' Concerns

Non-Executive Director recently bought HK$291k worth of stock

China Health Group Limited Announces Redesignation of Xing Yong from A Non- Executive Director to an Executive Director

Full year 2024 earnings released: HK$0.085 loss per share (vs HK$0.099 loss in FY 2023)

China Health Group Limited, Annual General Meeting, Sep 12, 2024

New minor risk - Shareholder dilution

Full year 2024 earnings released: HK$0.084 loss per share (vs HK$0.099 loss in FY 2023)

China Health Group Limited to Report Fiscal Year 2024 Results on Jun 27, 2024

First half 2024 earnings released: HK$0.032 loss per share (vs HK$0.066 loss in 1H 2023)

New major risk - Revenue and earnings growth

China Health Group Limited to Report First Half, 2024 Results on Nov 30, 2023

Shareholders Will Probably Not Have Any Issues With China Health Group Limited's (HKG:673) CEO Compensation

New minor risk - Shareholder dilution

China Health Group Limited, Annual General Meeting, Sep 18, 2023

Full year 2023 earnings released: HK$0.099 loss per share (vs HK$0.03 loss in FY 2022)

New minor risk - Insider selling

Full year 2023 earnings released: HK$0.099 loss per share (vs HK$0.03 loss in FY 2022)

China Health Group Limited to Report Fiscal Year 2023 Results on Jun 30, 2023

Executive Chairman recently bought HK$932k worth of stock

First half 2023 earnings released: HK$0.066 loss per share (vs HK$0.013 loss in 1H 2022)

We Think China Health Group (HKG:673) Has A Fair Chunk Of Debt

First half 2023 earnings released: HK$0.066 loss per share (vs HK$0.013 loss in 1H 2022)

China Health Group Limited Provides Earning Guidance for the Six Months Ended 30 September 2022

China Health Group Limited to Report First Half, 2023 Results on Nov 30, 2022

Less than half of directors are independent

We Discuss Why China Health Group Limited's (HKG:673) CEO May Deserve A Higher Pay Packet

China Health Group Limited, Annual General Meeting, Sep 30, 2022

Full year 2022 earnings released: HK$0.003 loss per share (vs HK$0.002 loss in FY 2021)

Full year 2022 earnings released

China Health Group Limited to Report Fiscal Year 2022 Results on Jun 30, 2022

China Health Group Limited announced that it expects to receive HKD 82 million in funding

Less than half of directors are independent

First half 2022 earnings: Revenues and EPS in line with analyst expectations

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Some Shareholders May Hesitate To Increase China Health Group Limited's (HKG:673) CEO Compensation

Full year 2021 earnings released: HK$0.002 loss per share (vs HK$0.009 loss in FY 2020)

No-Executive Director has left the company

China Health Group Limited Announces Board Changes

Did China Health Group Limited (HKG:673) Insiders Sell Shares?

First half 2021 earnings released: HK$0.001 loss per share

First half 2021 earnings released: HK$0.001 loss per share

China Health Group Limited to Report First Half, 2021 Results on Nov 30, 2020

Full year earnings released - HK$0.0089 loss per share

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines